Protara Therapeutics Inc (TARA) is trading down at $2.44 (-2.40%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Operating income | −$28.7M | −$30.4M | −$21.4M | −$7.83M | −$34.4M | −$47.5M | −$67.1M | −$43.6M | −$49.2M | −$64.5M |
| Net income | −$28.5M | −$30.0M | −$20.7M | −$7.83M | −$34.0M | −$47.3M | −$66.0M | −$40.4M | −$44.6M | −$57.4M |
| EPS (diluted) | −$247.68 | −$306.72 | −$4.12 | −$3.04 | −$4.70 | −$4.21 | −$5.86 | −$3.57 | −$2.17 | −$1.34 |
| Balance sheet | ||||||||||
| Cash and equivalents | $36.4M | $21.2M | $19.4M | $564.0K | $168.6M | $35.7M | $24.1M | $39.6M | $162.8M | $49.7M |
| Total assets | $43.5M | $44.0M | $23.5M | $1.22M | $203.2M | $172.6M | $113.3M | $79.0M | $181.5M | $209.5M |
| Total liabilities | $5.08M | $9.24M | $3.08M | $3.35M | $3.91M | $10.7M | $11.2M | $10.6M | $14.3M | $13.1M |
| Shareholders' equity | $38.4M | $34.7M | $4.78M | −$2.13M | $199.2M | $161.9M | $102.1M | $68.3M | $167.1M | $196.4M |
| Cash flow | ||||||||||
| Operating cash flow | −$23.7M | −$22.4M | −$23.2M | −$5.01M | −$23.4M | −$34.5M | −$26.5M | −$37.6M | −$35.8M | −$56.4M |
| Capital expenditure | $271.0K | $35.0K | $119.0K | $475.0K | $884.0K | $596.0K | $120.0K | $45.0K | $63.0K | $94.0K |
| Free cash flow | −$24.0M | −$22.4M | −$23.4M | −$5.49M | −$24.3M | −$35.1M | −$26.6M | −$37.6M | −$35.9M | −$56.5M |
| Share buybacks | — | — | — | — | — | $228.0K | $90.0K | $91.0K | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$12.3M | −$14.3M | −$14.1M | −$16.6M | −$14.8M | −$19.1M | −$19.6M | −$23.3M |
| Net income | −$11.2M | −$12.8M | −$11.9M | −$15.0M | −$13.3M | −$17.3M | −$17.8M | −$21.7M |
| EPS (diluted) | −$0.50 | −$0.25 | −$0.29 | −$0.35 | −$0.31 | −$0.39 | −$0.31 | −$0.36 |
| Balance sheet | ||||||||
| Cash and equivalents | $51.8M | $162.8M | $91.5M | $31.5M | $12.6M | $49.7M | $14.7M | $17.1M |
| Total assets | $94.1M | $181.5M | $168.6M | $156.9M | $144.6M | $209.5M | $191.9M | $176.1M |
| Total liabilities | $12.3M | $14.3M | $10.1M | $12.5M | $12.3M | $13.1M | $10.7M | $14.8M |
| Shareholders' equity | $81.8M | $167.1M | $158.5M | $144.4M | $132.3M | $196.4M | $181.2M | $161.3M |
| Cash flow | ||||||||
| Operating cash flow | −$8.43M | −$9.31M | −$14.7M | −$12.3M | −$12.5M | −$16.9M | −$21.3M | −$15.4M |
| Capital expenditure | $8.00K | $0 | $44.0K | $22.0K | $4.00K | $24.0K | — | — |
| Free cash flow | −$8.44M | −$9.31M | −$14.8M | −$12.3M | −$12.5M | −$17.0M | — | — |
From Protara Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Protara Therapeutics Inc in our feed yet.